![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » La Jolla Pharmaceutical Company Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney Disease
La Jolla Pharmaceutical Company Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney Disease
January 28, 2013
La Jolla Pharmaceutical, a leader in the development of therapeutics that target galectin-3, announced it has administered the first dose for its Phase I/II clinical trial of GCS-100 in patients with chronic kidney disease.
MarketWire
MarketWire
Upcoming Events
-
21Oct